Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
CStone Pharmaceuticals
2616Current price
1.81 HKD
-0.01 HKD (-0.55%)
Last closed
1.82 HKD
Company
www.cstonepharma.com
ISIN
KYG2588M1006
Sector
Healthcare
Industry
Biotechnology
Exchange
Hong Kong Stock Exchange
Capitalization
2 502 449 821 HKD
Yield for 12 month
-22.98 %
1Y
3Y
5Y
10Y
15Y
2616
CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; and Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation. Its products also comprise CS1002, CS2006, CS3005, CS2007, CS2008, CS6001, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Suzhou, China. Address: C1 Building, Suzhou, China, 215123
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
19.54 HKDP/E ratio
–Dividend Yield
–Current Year
+500 689 055 HKD
Last Year
+519 601 899 HKD
Current Quarter
+282 245 181 HKD
Last Quarter
–
Current Year
+328 467 835 HKD
Last Year
+300 492 020 HKD
Current Quarter
+165 625 853 HKD
Last Quarter
–
Key Figures 2616
1 year
3 years
5 years
10 years
EBITDA
-339 541 980 HKD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-13.91 %
PEG Ratio
–
Return On Equity TTM
-26.57 %
Wall Street Target Price
19.54 HKD
Revenue TTM
457 048 504 HKD
Book Value
0.37 HKD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-2.8 %
Dividend Yield
–
Gross Profit TTM
137 040 570 HKD
Earnings per share
–
Diluted Eps TTM
–
Most Recent Quarter
II 2023
Quarterly Earnings Growth YOY
–
Profit Margin
-31.17 %
Dividend Analytics 2616
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 2616
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation 2616
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
4.005
Price Sales TTM
5.4752
Enterprise Value EBITDA
-2.194
Price Book MRQ
4.9344
Financials 2616
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 2616
For 52 weeks
0.8 HKD
2.95 HKD
50 Day MA
1.73 HKD
Shares Short Prior Month
–
200 Day MA
1.35 HKD
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart